


SEL Inflammatory Bowel Disease, Outcomes and Monitoring Framework
April 2025 to March 2026



An overarching value description for the SEL IBD Pathway is demonstrated by the pyramid below, partnered with a set of Key Performance Indicators to assign specific monitoring to some elements.



Key Outcomes

The following NHS Outcomes Framework 2020 indicators have been chosen as key outcome measures;

1. Domain 2. Enhancing the quality of life for people with long term conditions. High quality outcomes are commissioned and delivered in line with current best practice and high value (see related guidelines at <http://www.nice.org.uk/> and [SEL IBD Pathway](#)).
2. Domain 4. Ensuring that people have a positive experience of care. Care is commissioned and delivered line with NICE Quality standards for Patient Experience (<http://www.nice.org.uk/guidance/QS15/>) and IBD (<https://www.nice.org.uk/guidance/qs81>). To improve the quality of care for individual patients and their carers living with Inflammatory Bowel Disease and ensure care is well co-ordinated around their needs through a robust care planning and shared goal setting approach.

Measures:

KPI	Intervention	Target	Measure and frequency	Data Source	Who measures	Frequency of reporting – in any financial year
1	Review of all IBD patients on biologic therapies (Pathway 4a and 4b) at one year and every subsequent year via multidisciplinary clinic	99% of all IBD patients on biologic therapies (Pathways 4a & 4b) are reviewed at one year and every subsequent year via multidisciplinary clinic	Snapshot audit based on quarter 3 (Oct – Dec 2025) in 25/26: (x) The numbers of IBD patients under the care of the service on a biologic who have been reviewed in the last 12 months at the MDT VC. (y) The numbers of IBD patients under the care of the service on a biologic. [x/y] x 100 = the percentage of IBD patients under the care of the service on a biologic who have been reviewed in the last 12 months at the MDT VC.	Biologics registry or Trust Database	Trust	Annual Report – to cover a snapshot audit

SEL Inflammatory Bowel Disease, Outcomes and Monitoring Framework
April 2025 to March 2026



2	Review sequential use of biologic therapies in Crohn's disease and ulcerative colitis (following failure of 4 or more treatment options with different mechanisms of action)	Patients receiving sequential biologic therapies following failure of 4 or more treatment options with different mechanisms of action in line with the local SEL pathway	<p>Snapshot audit based on quarter 1 (Apr – June 2025) in 25/26 and SEL patients only.</p> <p>Audit to demonstrate:</p> <ul style="list-style-type: none"> • Compliance with pathway (100%) • Number of patients who have received sequential biologic treatments following failure of 4 or more treatment options with different mechanisms of action and the treatments received • Number of patients initiated on the best value biologic in line with the SEL pathway • Broad themes on reasons for stopping treatment* • Clinical outcomes/benefits for patients <p>*For dose escalation, please also outline number of patients de-escalated</p>	Biologics registry or Trust Database	Trust	Annual Report – to cover a snapshot audit
3	Audit of locally commissioned elements of the pathway: Audit of dual advanced therapy in Crohn's disease (off-label)	<ul style="list-style-type: none"> • 100% of patients meet the agreed criteria for use of dual advanced therapy 	<p>Audit to demonstrate:</p> <ul style="list-style-type: none"> • Compliance with pathway (100%) • Number of patients initiated, and the dual advanced therapy combinations initiated • Number of patients stopping (and broad themes on reasons) • Clinical outcomes/benefits for patients • Any safety concerns 	Trusts	Trust database	Annual
4	Measure impact of the pathway on overall service commissioning costs to ensure value for money	High cost drugs use (Biologics) in SEL ICB	Quarterly breakdown of biologics use and cost by indication for Crohn's Disease and Ulcerative Colitis by Trust, for SEL ICB	Acute activity	SEL ICB Business Intelligence	Quarterly review of data

Approved by:

- SEL IBD Pathway Group – June 2025
- SEL Integrated Medicines Optimisation Committee – August 2025
- **Review date:** April 2026